Jonathan Violin - Feb 1, 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Executive Officer, Director
Signature
/s/ Lara Meisner, Attorney-in-Fact for Jonathan Violin
Stock symbol
VRDN
Transactions as of
Feb 1, 2022
Transactions value $
-$572,818
Form type
4
Date filed
2/3/2022, 05:11 PM
Previous filing
Dec 10, 2021
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Sale -$327K -16.8K -2.66% $19.55 614K Feb 1, 2022 Direct F1
transaction VRDN Common Stock Sale -$228K -12.3K -2.01% $18.47 602K Feb 2, 2022 Direct F2
transaction VRDN Common Stock Sale -$17.4K -909 -0.15% $19.16 601K Feb 3, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Award $0 +280K $0.00 280K Feb 2, 2022 Common Stock 280K $18.51 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.90 to $20.23. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.32 to $19.49. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.04 to $19.66. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.